Long Term Result of Modified 6+3 Bacillus Calmette-Guerin Maintenance Therapy for Non-muscle-invasive Bladder Cancer in Korea: Comparison of 6-week Therapy
Journal of Urologic Oncology 2014³â 12±Ç 2È£ p.65 ~ p.70
°Çʹ®(Kang Pil-Moon) - Inje University Busan Paik Hospital Department of Urology
¼¿øÀÍ(Seo Won-Ik) - Inje University Busan Paik Hospital Department of Urology
Á¤ÀçÀÏ(Chung Jae-Il) - Inje University Busan Paik Hospital Department of Urology
Abstract
Purpose: We report our experience with modified 6£«3 maintenance BCG therapy compared with a 6-week induction course over the past 10 years and its effects on recurrence and progression.
Materials and Methods: Between January 2001 and June 2012, a total of 181 patients treated with NMIBC underwent TUR and intravesical BCG. BCG was administered over a 6-week course in 88 patients, and was administered for six weeks followed by three weekly instillations at 3, 6, 9, 12, 18, 24, and 36 months (modified 6£«3 regimen) in 93 patients. The recurrence rate, time to recurrence, and progression rate were assessed and analyzed.
Results: A total of 30 of 181 patients were ineligible. Seventy-three patients in the 6-week induction group and seventy-eight patients in maintenance group were eligible. Median follow-up was 37.4 months in the maintenance group and 32.9 months in the 6-week course group. The estimated overall recurrence rate and median recurrence-free survival were 21.8% (17/78) and 23.4 months (95% confidence interval [CI] 7-84) in the maintenance group and 35.6% (26/73) and 21.5 months (6-80) in the 6-week course group (log rank p=0.002), respectively. Estimated median times for progression-free survival were 44.0 months (95% CI 7-84) in the maintenance group and 25.7 months (14-41) in the 6-week course group (log rank p=0.0815). The overall rates of adverse effects were 27.9% (26/93) in the maintenance group and 25.0% (22/88) in the 6-week course group.
Conclusions: Compared to the standard 6-week course, maintenance BCG immunotherapy was beneficial for preventing recurrence in patients with non-muscle-invasive bladder cancer.
Å°¿öµå
Bladder cancer, Calmette-Guerin Bacillus, Maintenance
KMID :
1001020140120020065
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)